A Disposable Negative Pressure Wound Therapy Device (SNaP) to Promote Wound Healing in the Lower Limbs Following Mohs Micrographic Surgery for Non-melanoma Skin Cancer
Part of paid clinical trials in Los Angeles, California.
- Sponsor
- Jonsson Comprehensive Cancer Center
- Study ID
- NCT07032701
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Skin Carcinoma
Eligibility Criteria
- Sex
- ALL
- Age
- 19 Years - 79 Years
- Healthy Volunteers
- Not accepted
Interventions
- Best Practice — OTHERUndergo SOC non-adherent dressing wound care
- Educational Intervention — OTHERReceive SNaP education
- Educational Intervention — OTHERReceive SOC wound care education
- Electronic Health Record Review — OTHERAncillary studies
- Follow-Up Care — OTHERAttend SNaP device follow-up visits
- Follow-Up Care — OTHERAttend SOC wound care follow-up visits
- Medical Device Usage and Evaluation — OTHERUndergo dNPWT with SNaP device
- Negative Pressure Wound Therapy — PROCEDUREUndergo dNPWT with SNaP device
- Photography — OTHERAncillary studies
- Questionnaire Administration — OTHERAncillary studies
Study Details
This clinical trial studies whether a disposable negative pressure wound therapy (dNPWT) device, SNaP Wound Care System (Ultraportable Mechanically Powered Negative Pressure Wound Therapy) (SNaP), promotes wound healing in the lower limbs in patients that have undergone Mohs micrographic surgery (Mohs surgery) for non-melanoma skin cancer. Mohs surgery is a surgical technique used to treat skin cancer. Individual layers of cancerous tissue are removed and examined under a microscope one at a time until all cancerous tissue has been removed. It is an important part of removing skin cancer, but it often leads to soft-tissue defects and reconstructive challenges, especially in high-tension areas like the lower limbs. Typically, these wounds are managed by leaving them open and allowing them to heal from the base up or are reconstructed by transferring healthy skin from another part of the body. Negative pressure wound therapy (NPWT) is a wound dressing system that continuously or intermittently applies subatmospheric pressure to the surface of a wound to draw out fluid and promote healing. The SNaP device is a dNPWT device for lower leg wound healing designed for increased portability and ease of use outside of a hospital setting. It is a modification of traditional NPWT devices that uses springs to generate pressure, making it lighter and more user-friendly than traditional devices that rely on electrically powered pumps. This may be a more effective way to promote wound healing in the lower limbs following Mohs surgery for non-melanoma skin cancer.
Key Dates
- Start date
- Jun 30, 2026
- Status verified
- Apr 2026
- Primary completion
- Jun 30, 2030
- Completion
- Jun 30, 2031
Study Design
- Enrollment
- 60 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- SUPPORTIVE_CARE
Arms
- Experimental: Group 1 (SNaP device dNPWT)Patients undergo dNPWT with SNaP device following SOC Mohs surgery and attend follow-up visits with re-application of SNaP device over 30 minutes QW, as needed until complete wound healing is achieved, for up to 12 weeks. Patients also receive education regarding SNaP device application and informational/educational SNaP device handouts on study.
- Active Comparator: Group 2 (SOC wound care)Patients undergo SOC wound care with non-adherent dressing following SOC Mohs surgery and attend follow-up visits with non-adherent dressing changes over 30 minutes QW, as needed until complete wound healing is achieved, for up to 12 weeks. Patients also receive education on SOC wound dressing changes on study.
Primary Outcome Measure
Wound healing duration [ Time Frame: Up to 12 weeks ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| UCLA / Jonsson Comprehensive Cancer Center | Los Angeles | California | 90095 | Jeremy C. Davis Jeremy C. Davis (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Los Angeles, CA
Related Studies
- Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic CancersPHASE1 · Recruiting · Jonsson Comprehensive Cancer Center · Los Angeles, California
- Cancer Genetic Testing in Ethnic PopulationsRecruiting · Mayo Clinic · Scottsdale, Arizona